Antiarrhythmic drugs

  • Steven N. Singh
  • Jonathan Patrick
Article

Opinion statement

Both supraventricular and ventricular arrhythmias are associated with increased mortality and morbidity. Numerous antiarrhythmics have been developed in an attempt to decrease the frequency of these arrhythmias, hoping to improve survival and improve quality of life. Antiarrhythmic agents are a diverse group of drugs that affect various cardiac ionic channels and block specific arrhythmias. However, despite the suppression of these potentially lethal cardiac arrhythmias, only the β blockers have been shown to reduce sudden arrhythmic death, especially in patients with prior myocardial infarction or heart failure. Some antiarrhythmic agents can also worsen the index arrhythmia and caution must be used especially in the compromised patient. A simple guideline is as follows: For conversion of atrial fibrillation or flutter to sinus rhythm, in the absence of structural heart disease, intravenous ibutilide or oral propafenone or flecainide are good choices. For maintenance of sinus rhythm, propafenone or flecainide are logical choices. In the presence of structural heart disease, amiodarone, dofetilide, or dl sotalol are preferred. In heart failure, dofetilide or amiodarone are the logical choices. The role of antiarrhythmic therapy for ventricular arrhythmias is questionable and may be contraindicated, except for the use of β blockers. The implantable cardioverter-defibrillator is often used in patients at high risk. At times, the addition of an antiarrhythmic agent such as amiodarone may be justified.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmic Suppression Trial (CAST) Investigators [no authors listed]. N Engl J Med 1989, 321:406–412.Google Scholar
  2. 2.
    Ryden L, Ariniego R, Arnman K, et al.: A double-blind trial of metropolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med 1983, 308:614–618.PubMedCrossRefGoogle Scholar
  3. 3.
    Poole-Wilson PA, Swedberg K, Cleland JG, et al.: Comparison of carvedilol and metropolol on clinical outcomes in patients with chronic heart failure in the COMET: randomized controlled trial. Lancet 2003, 362:7–13.PubMedCrossRefGoogle Scholar
  4. 4.
    A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. The Beta-Blocker Evaluation of Survival Trial Investigators [no authors listed]. N Engl J Med 2001, 344:1659–1667.Google Scholar
  5. 5.
    Doval HC, Nul DR, Grancelli HO, et al.: Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994, 344:493–498.PubMedCrossRefGoogle Scholar
  6. 6.
    Singh SN, Fletcher RD, Fisher SG, et al.: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995, 333:77–82.PubMedCrossRefGoogle Scholar
  7. 7.
    Kober L, Bloch Thomsen PE, Moller M, et al.: Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomized trial. Lancet 2000, 356:2052–2058.PubMedCrossRefGoogle Scholar
  8. 8.
    Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al.: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999, 341:857–864.PubMedCrossRefGoogle Scholar
  9. 9.
    Julian DG, Prescott RJ, Jackson FS, Szekely P: Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982, 1:1142–1147.PubMedCrossRefGoogle Scholar
  10. 10.
    Fuster V, Ryden LE, Asinger RW, et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001, 38:1231–1266. Excellent summary of choices for sinus rhythm in patients with atrial fibrillation.PubMedCrossRefGoogle Scholar
  11. 11.
    The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group [no authors listed]. N Engl J Med 1997, 336:515–533.Google Scholar
  12. 12.
    Latini R, Magginoi AP, Flather M, et al.: ACE inhibitor use in patients with myocardial infraction. Summary of evidence from clinical trials. Circulation 1995, 92:3132–3137.PubMedGoogle Scholar
  13. 13.
    Kober L, Torp-Pedersen C, Carlsen JE, et al.: A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995, 333:1670–1676.PubMedCrossRefGoogle Scholar
  14. 14.
    Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study [no authors listed]. Lancet 1993, 342:821–828.Google Scholar
  15. 15.
    Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153.PubMedCrossRefGoogle Scholar
  16. 16.
    Pedersen OD, Bagger H, Kober L, Torp-Pedersen C: Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999, 100:376–380.PubMedGoogle Scholar
  17. 17.
    Vermes E, Tardif JC, Bourassa MG, et al.: Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003, 107:2926–2931.PubMedCrossRefGoogle Scholar
  18. 18.
    Pitt B, Zannad R, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709–717.PubMedCrossRefGoogle Scholar
  19. 19.
    Pitt B, Remme W, Zannad F, et al.: Eplernone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309–1321.PubMedCrossRefGoogle Scholar
  20. 20.
    Marchioli R, Barzi F, Bomba E, et al.: Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction. Circulation 2002, 105:1897–1903.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Steven N. Singh
    • 1
  • Jonathan Patrick
    • 1
  1. 1.CardiologyVA Medical CenterWashingtonUSA

Personalised recommendations